Inventor
TURNER SEAN COLM
DE23 patents
⚠️ This page may combine multiple inventors who share the name “TURNER SEAN COLM”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
TURNER SEAN COLM
7 patentsUS8440694B2May 14, 2013
Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin-5-HT6 receptor
TURNER SEAN COLM12 citations83
US9090592B2Jul 28, 2015
Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
TURNER SEAN COLM6 citations82
US9266855B2Feb 23, 2016
Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
TURNER SEAN COLM11 citations81
US8318793B2Nov 27, 2012
Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
TURNER SEAN COLM17 citations81
US8242102B2Aug 14, 2012
Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
TURNER SEAN COLM2 citations60
US8455648B2Jun 4, 2013
1-(7-(hexahydropyrrolo [3,4-c] pyrrol-2 (1H)-yl) quinolin-4-yl) -3- (pyrazin-2-yl) urea derivatives and related compounds as glycogen synthase kinase 3 (GSK-3)
TURNER SEAN COLM1 citations51
US8293913B2Oct 23, 2012
Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin-5-HT6 receptor
TURNER SEAN COLM0 citations50
CIBA SC HOLDING AG
4 patentsUS6410628B1Jun 25, 2002
Photoactivatable nitrogen-containing bases based on alpha-amino ketones
CIBA SC HOLDING AG21 citations92
US6277986B1Aug 21, 2001
Photoactivatable nitrogen-containing bases based on α-amino ketones
CIBA SC HOLDING AG23 citations92
US6087070AJul 11, 2000
Photoactivatable nitrogen-containing bases based on α-amino alkenes
CIBA SC HOLDING AG25 citations92
US6489374B1Dec 3, 2002
Photoactivatable bases containing nitrogen
CIBA SC HOLDING AG16 citations79
ABBVIE DEUTSCHLAND
3 patentsUS9790203B2Oct 17, 2017
Inhibitor compounds of phosphodiesterase type 10A
ABBVIE DEUTSCHLAND2 citations62
US9540370B2Jan 10, 2017
Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
ABBVIE DEUTSCHLAND0 citations51
US10100048B2Oct 16, 2018
Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
ABBVIE DEUTSCHLAND0 citations49
ABBOTT GMBH & CO KG
2 patentsUS7790727B2Sep 7, 2010
Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
ABBOTT GMBH & CO KG4 citations60
US8383641B2Feb 26, 2013
Aryloxyethylamine compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
ABBOTT GMBH & CO KG0 citations41
BRAJE WILFRIED
2 patentsUS8492540B2Jul 23, 2013
1,2,4,-triazin-3,5-dione compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
BRAJE WILFRIED0 citations51
US8476275B2Jul 2, 2013
N-[piperazinyl hetaryl]arylsufonamide compounds with affinity for the dopamine D3 receptor
BRAJE WILFRIED0 citations41
GRANDEL ROLAND
2 patentsUS8497273B2Jul 30, 2013
Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor
GRANDEL ROLAND0 citations35
US8642642B2Feb 4, 2014
Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor
GRANDEL ROLAND0 citations32